Experienced in Squamous Cell Lung Carcinoma

Tetsuhiko Taira

Kagoshima, JP 
Experienced in Squamous Cell Lung Carcinoma
Kagoshima, JP 
OverviewLocationsClinical Research

Overview

Tetsuhiko Taira practices in Kagoshima, Japan. Taira is rated as an Experienced expert by MediFind in the treatment of Squamous Cell Lung Carcinoma. Their top areas of expertise are Non-Small Cell Lung Cancer (NSCLC), Lung Cancer, Agranulocytosis, and EGFR Positive Lung Cancer.

Their clinical research consists of co-authoring 62 peer reviewed articles and participating in 3 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, they have co-authored 2 articles in the study of Squamous Cell Lung Carcinoma.

Locations

Kagoshima, Japan
Other Locations
Matsubara, 8920098, Japan
Shizuoka, Japan
Kurume, Japan
Kashiwa, 2778577, Japan
Aira, 8995241, Japan
Shimonagakubo, 4118777, Japan

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

3 Clinical Trials

Randomized, Double-blind, Phase 3 Study of Tucatinib or Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Subjects With Unresectable Locally-advanced or Metastatic HER2+ Breast Cancer (HER2CLIMB-02)
Randomized, Double-blind, Phase 3 Study of Tucatinib or Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Subjects With Unresectable Locally-advanced or Metastatic HER2+ Breast Cancer (HER2CLIMB-02)
Enrollment Status: Active_not_recruiting
Publish Date: August 07, 2025
Intervention Type: Drug
Study Drugs: tucatinib, T-DM1
Study Phase: Phase 3
A Randomized Phase 3 Double-Blinded Study Comparing the Efficacy and Safety of Niraparib to Placebo in Participants With Either HER2-Negative BRCA-Mutated or Triple-Negative Breast Cancer With Molecular Disease Based on Presence of Circulating Tumor DNA After Definitive Therapy (ZEST)
A Randomized Phase 3 Double-Blinded Study Comparing the Efficacy and Safety of Niraparib to Placebo in Participants With Either HER2-Negative BRCA-Mutated or Triple-Negative Breast Cancer With Molecular Disease Based on Presence of Circulating Tumor DNA After Definitive Therapy (ZEST)
Enrollment Status: Active_not_recruiting
Publish Date: July 16, 2025
Intervention Type: Drug
Study Drug: Niraparib
Study Phase: Phase 3
EMBER-3: A Phase 3, Randomized, Open-Label Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Patients With Estrogen Receptor Positive, HER2 Negative Locally Advanced or Metastatic Breast Cancer Previously Treated With Endocrine Therapy
EMBER-3: A Phase 3, Randomized, Open-Label Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Patients With Estrogen Receptor Positive, HER2 Negative Locally Advanced or Metastatic Breast Cancer Previously Treated With Endocrine Therapy
Enrollment Status: Active_not_recruiting
Publish Date: July 11, 2025
Intervention Type: Drug
Study Drugs: Imlunestrant, Exemestane, Fulvestrant, Abemaciclib
Study Phase: Phase 3
View 2 Less Clinical Trials

62 Total Publications

Electronic Patient-Reported Outcomes With Vital Sign Monitoring During Trastuzumab Deruxtecan Therapy: The PRO-DUCE Randomized Clinical Trial.
Electronic Patient-Reported Outcomes With Vital Sign Monitoring During Trastuzumab Deruxtecan Therapy: The PRO-DUCE Randomized Clinical Trial.
Journal: JAMA network open
Published: August 15, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Taira's expertise for a condition
ConditionClose
    View All 8 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile